FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Effects of intravenous administration of peripheral blood-de...
Journal of veterinary internal medicine2022; 36(4); 1491-1501; doi: 10.1111/jvim.16447

Effects of intravenous administration of peripheral blood-derived mesenchymal stromal cells after infusion of lipopolysaccharide in horses.

Abstract: A systemic and dysregulated immune response to infection contributes to morbidity and mortality associated with sepsis. Peripheral blood-derived mesenchymal stromal cells (PB-MSC) mitigate inflammation in animal models of sepsis. Allogeneic PB-MSC administered IV to horses is well-tolerated but therapeutic benefits are unknown. Objective: After IV lipopolysaccharide (LPS) infusion, horses treated with PB-MSC would have less severe clinical signs, clinicopathological abnormalities, inflammatory cytokine gene expression, and oxidative stress compared to controls administered a placebo. Methods: Sixteen horses were included in this study. Methods: A randomized placebo-controlled experimental trial was performed. Sixteen healthy horses were assigned to 1 of 2 treatment groups (1 × 10  PB-MSC or saline placebo). Treatments were administered 30 minutes after completion of LPS infusion of approximately 30 ng/kg. Clinical signs, clinicopathological variables, inflammatory cytokine gene expression, and oxidative stress markers were assessed at various time points over a 24-hour period. Results: A predictable response to IV LPS infusion was observed in all horses. At the dose administered, there was no significant effect of PB-MSC on clinical signs, clinicopathological variables, or inflammatory cytokine gene expression at any time point. Antioxidant potential was not different between treatment groups, but intracellular ROS increased over time in the placebo group. Other variables that changed over time were likely due to effects of IV LPS infusion. Conclusions: Administration of allogeneic PB-MSC did not cause clinically detectable adverse effects in healthy horses. The dose of PB-MSC used here is unlikely to exert a beneficial effect in endotoxemic horses.
© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2022-06-14 PubMed ID: 35698909PubMed Central: PMC9308407DOI: 10.1111/jvim.16447Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is a scientific study investigating the impact of administering mesenchymal stromal cells derived from peripheral blood (PB-MSC) to horses after inducing a systemic inflammatory response. It concludes that while the PB-MSC do not cause adverse effects, they also did not present noticeable benefits in treating the induced inflammatory condition at the administered dose.

Objective of the Study

The main goal of this study was to investigate whether treating horses with PB-MSC after inducing a systemic inflammatory response with lipopolysaccharide (LPS), would reduce clinical signs of inflammation, pathological abnormalities, inflammatory cytokine gene expression and oxidative stress compared to horses treated with a placebo.

Methodology

  • Sixteen healthy horses were randomly assigned into two treatment groups— each receiving either an intravenous dose of PB-MSC or a saline placebo.
  • The treatments were administered half an hour post completion of the LPS infusion, which was given at approximately 30 nanogrammes per kilogramme of the horse’s body weight.
  • Various parameters such as clinical signs, pathological variables, inflammatory cytokine gene expression, and markers of oxidative stress were assessed at different time points over a twenty-four-hour period.

Results

  • All the horses reacted in a predictable manner to the intravenous infusion of LPS.
  • The administration of PB-MSC did not have any significant effect on the clinical symptoms, pathological changes, or gene expressions related to inflammation at any point in time.
  • The antioxidant potential remained unchanged across both treatment groups, but there was an observed increase in intracellular Reactive Oxygen Species (ROS) with time in the group that received the placebo.
  • Other variables that changed over time were attributed to the effects of the intravenous infusion of LPS.

Conclusion

The authors concluded that the administration of allogeneic PB-MSC caused no clinically detectable adverse effects in the horses. However, they also stated that the dose of PB-MSC used in this study is unlikely to exert a beneficial effect in treating horses with endotoxemic conditions. This suggests that while PB-MSC may be safely administered to horses, the therapeutic benefits at the administered dose were inconclusive, justifying further examination at different dosages or administration methods.

Cite This Article

APA
Taylor SD, Serpa PBS, Santos AP, Hart KA, Vaughn SA, Moore GE, Mukhopadhyay A, Page AE. (2022). Effects of intravenous administration of peripheral blood-derived mesenchymal stromal cells after infusion of lipopolysaccharide in horses. J Vet Intern Med, 36(4), 1491-1501. https://doi.org/10.1111/jvim.16447

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 36
Issue: 4
Pages: 1491-1501

Researcher Affiliations

Taylor, Sandra D
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Serpa, Priscila B S
  • Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Santos, Andrea P
  • Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Hart, Kelsey A
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Vaughn, Sarah A
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Moore, George E
  • Department of Veterinary Administration, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Mukhopadhyay, Abhijit
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Page, Allen E
  • Gluck Equine Research Center, College of Agriculture, Food and Environment, University of Kentucky, Lexington, Kentucky, USA.

MeSH Terms

  • Animals
  • Cytokines / genetics
  • Cytokines / metabolism
  • Endotoxemia / veterinary
  • Horse Diseases / drug therapy
  • Horses
  • Infusions, Intravenous / veterinary
  • Lipopolysaccharides
  • Mesenchymal Stem Cells / metabolism

Grant Funding

  • 1016369 / USDA National Institute of Food and Agriculture
  • Purdue University AgSEED Agricultural Research and Extension Program
  • 208453 / Purdue University Showalter Trust

Conflict of Interest Statement

George E. Moore serves as Consulting Editor for Experimental Design and Statistics for the Journal of Veterinary Internal Medicine. He was not involved in review of this manuscript. No other authors have a conflict of interest.

References

This article includes 65 references
  1. Cohen ND. Causes of and farm management factors associated with disease and death in foals.. J Am Vet Med Assoc 1994 May 15;204(10):1644-51.
    pubmed: 8050947
  2. Peek SF, Semrad S, McGuirk SM, Riseberg A, Slack JA, Marques F, Coombs D, Lien L, Keuler N, Darien BJ. Prognostic value of clinicopathologic variables obtained at admission and effect of antiendotoxin plasma on survival in septic and critically ill foals.. J Vet Intern Med 2006 May-Jun;20(3):569-74.
    pubmed: 16734091doi: 10.1892/0891-6640(2006)20[569:pvocvo]2.0.co;2google scholar: lookup
  3. Arroyo MG, Slovis NM, Moore GE, Taylor SD. Factors Associated with Survival in 97 Horses with Septic Pleuropneumonia.. J Vet Intern Med 2017 May;31(3):894-900.
    pmc: PMC5435057pubmed: 28271546doi: 10.1111/jvim.14679google scholar: lookup
  4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.. Chest 1992 Jun;101(6):1644-55.
    pubmed: 1303622doi: 10.1378/chest.101.6.1644google scholar: lookup
  5. Werners AH, Bull S, Fink-Gremmels J. Endotoxaemia: a review with implications for the horse.. Equine Vet J 2005 Jul;37(4):371-83.
    pubmed: 16028631doi: 10.2746/0425164054529418google scholar: lookup
  6. Castagnetti C, Mariella J, Pirrone A, Cinotti S, Mari G, Peli A. Expression of interleukin-1β, interleukin-8, and interferon-γ in blood samples obtained from healthy and sick neonatal foals.. Am J Vet Res 2012 Sep;73(9):1418-27.
    pubmed: 22924724doi: 10.2460/ajvr.73.9.1418google scholar: lookup
  7. Pusterla N, Magdesian KG, Mapes S, Leutenegger CM. Expression of molecular markers in blood of neonatal foals with sepsis.. Am J Vet Res 2006 Jun;67(6):1045-9.
    pubmed: 16740100doi: 10.2460/ajvr.67.6.1045google scholar: lookup
  8. Fratto MA, Hart KA, Norton NA, Barton MH, Giguère S, Hurley DJ. The effect of free and carrier-bound cortisol on equine neutrophil function.. Vet Immunol Immunopathol 2017 Jan;183:16-21.
    pubmed: 28063472doi: 10.1016/j.vetimm.2016.11.003google scholar: lookup
  9. Borba LA, Nogueira CEW, Bruhn FRP, da Silva GC, Feijó LS, Canisso IF, Curcio BDR. Peripheral blood markers of sepsis in foals born from mares with experimentally induced ascending placentitis.. Vet Rec 2020 Jul;187(1):29.
    pubmed: 33638540doi: 10.1136/vr.104710google scholar: lookup
  10. Anderson MJ, Ibrahim AS, Cooper BR, Woolcock AD, Moore GE, Taylor SD. Effects of administration of ascorbic acid and low-dose hydrocortisone after infusion of sublethal doses of lipopolysaccharide to horses.. J Vet Intern Med 2020 Nov;34(6):2710-2718.
    pmc: PMC7694830pubmed: 33026127doi: 10.1111/jvim.15896google scholar: lookup
  11. Barton MH, Bruce EH, Moore JN, Norton N, Anders B, Morris DD. Effect of tumor necrosis factor antibody given to horses during early experimentally induced endotoxemia.. Am J Vet Res 1998 Jun;59(6):792-7.
    pubmed: 9622754
  12. Jacobs CC, Holcombe SJ, Cook VL, Gandy JC, Hauptman JG, Sordillo LM. Ethyl pyruvate diminishes the inflammatory response to lipopolysaccharide infusion in horses.. Equine Vet J 2013 May;45(3):333-9.
    pubmed: 22943507doi: 10.1111/j.2042-3306.2012.00634.xgoogle scholar: lookup
  13. Nieto JE, MacDonald MH, Braim AE, Aleman M. Effect of lipopolysaccharide infusion on gene expression of inflammatory cytokines in normal horses in vivo.. Equine Vet J 2009 Sep;41(7):717-9.
    pubmed: 19927593doi: 10.2746/042516409x464780google scholar: lookup
  14. MacKay RJ, Lester GD. Induction of the acute-phase cytokine, hepatocyte-stimulating factor/interleukin 6, in the circulation of horses treated with endotoxin.. Am J Vet Res 1992 Aug;53(8):1285-9.
    pubmed: 1510298
  15. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.. Blood 2008 Feb 1;111(3):1327-33.
    pubmed: 17951526doi: 10.1182/blood-2007-02-074997google scholar: lookup
  16. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells.. Vet Surg 2007 Oct;36(7):613-22.
    pubmed: 17894587doi: 10.1111/j.1532-950x.2007.00313.xgoogle scholar: lookup
  17. De Schauwer C, Goossens K, Piepers S, Hoogewijs MK, Govaere JL, Smits K, Meyer E, Van Soom A, Van de Walle GR. Characterization and profiling of immunomodulatory genes of equine mesenchymal stromal cells from non-invasive sources.. Stem Cell Res Ther 2014 Jan 13;5(1):6.
    pmc: PMC4055120pubmed: 24418262doi: 10.1186/scrt395google scholar: lookup
  18. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    pmc: PMC3495591pubmed: 23152950doi: 10.3727/215517912x647217google scholar: lookup
  19. Broeckx S, Borena BM, Zimmerman M, Mariën T, Seys B, Suls M, Duchateau L, Spaas JH. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.. Curr Stem Cell Res Ther 2014;9(6):452-7.
    pubmed: 24548143doi: 10.2174/1574888x09666140220003847google scholar: lookup
  20. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.. Stem Cells 2006 May;24(5):1294-301.
    pubmed: 16410387doi: 10.1634/stemcells.2005-0342google scholar: lookup
  21. Shin S, Kim Y, Jeong S, Hong S, Kim I, Lee W, Choi S. The therapeutic effect of human adult stem cells derived from adipose tissue in endotoxemic rat model.. Int J Med Sci 2013;10(1):8-18.
    pmc: PMC3534872pubmed: 23289000doi: 10.7150/ijms.5385google scholar: lookup
  22. Zhang S, Danchuk SD, Imhof KM, Semon JA, Scruggs BA, Bonvillain RW, Strong AL, Gimble JM, Betancourt AM, Sullivan DE, Bunnell BA. Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury.. Stem Cell Res Ther 2013 Jan 29;4(1):13.
    pmc: PMC3706907pubmed: 23360775doi: 10.1186/scrt161google scholar: lookup
  23. Bosmann M, Meta F, Ruemmler R, Haggadone MD, Sarma JV, Zetoune FS, Ward PA. Regulation of IL-17 family members by adrenal hormones during experimental sepsis in mice.. Am J Pathol 2013 Apr;182(4):1124-30.
    pmc: PMC3620417pubmed: 23499051doi: 10.1016/j.ajpath.2013.01.005google scholar: lookup
  24. Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Leñero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.. Stem Cells Transl Med 2021 May;10(5):660-673.
    pmc: PMC8046040pubmed: 33400390doi: 10.1002/sctm.20-0472google scholar: lookup
  25. Lin CS, Lin G, Lue TF. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants.. Stem Cells Dev 2012 Oct 10;21(15):2770-8.
    pmc: PMC3806387pubmed: 22621212doi: 10.1089/scd.2012.0176google scholar: lookup
  26. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lönnies H, Nava S, Ringdén O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.. Leukemia 2007 Aug;21(8):1733-8.
    pubmed: 17541394doi: 10.1038/sj.leu.2404777google scholar: lookup
  27. Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, Xu J. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro.. Immunology 2009 Feb;126(2):220-32.
    pmc: PMC2632684pubmed: 18624725doi: 10.1111/j.1365-2567.2008.02891.xgoogle scholar: lookup
  28. Kilcoyne I, Nieto JE, Watson JL, Galuppo LD, Borjesson DL. Do allogeneic bone marrow derived mesenchymal stem cells diminish the inflammatory response to lipopolysaccharide infusion in horses? A pilot study.. Vet Immunol Immunopathol 2021 Jan;231:110146.
    pubmed: 33221572doi: 10.1016/j.vetimm.2020.110146google scholar: lookup
  29. Williams LB, Co C, Koenig JB, Tse C, Lindsay E, Koch TG. Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.. Front Vet Sci 2016;3:56.
    pmc: PMC4956649pubmed: 27500136doi: 10.3389/fvets.2016.00056google scholar: lookup
  30. Mund SJK, Kawamura E, Awang-Junaidi AH, Campbell J, Wobeser B, MacPhee DJ, Honaramooz A, Barber S. Homing and Engraftment of Intravenously Administered Equine Cord Blood-Derived Multipotent Mesenchymal Stromal Cells to Surgically Created Cutaneous Wound in Horses: A Pilot Project.. Cells 2020 May 8;9(5).
    pmc: PMC7290349pubmed: 32397125doi: 10.3390/cells9051162google scholar: lookup
  31. Martinello T, Bronzini I, Maccatrozzo L, Iacopetti I, Sampaolesi M, Mascarello F, Patruno M. Cryopreservation does not affect the stem characteristics of multipotent cells isolated from equine peripheral blood.. Tissue Eng Part C Methods 2010 Aug;16(4):771-81.
    pubmed: 19839741doi: 10.1089/ten.tec.2009.0512google scholar: lookup
  32. Spaas JH, De Schauwer C, Cornillie P, Meyer E, Van Soom A, Van de Walle GR. Culture and characterisation of equine peripheral blood mesenchymal stromal cells.. Vet J 2013 Jan;195(1):107-13.
    pubmed: 22717781doi: 10.1016/j.tvjl.2012.05.006google scholar: lookup
  33. Pritchett LC, Ulibarri C, Roberts MC, Schneider RK, Sellon DC. Identification of potential physiological and behavioral indicators of postoperative pain in horses after exploratory celiotomy for colic.. Appl Anim Behav Sci 2003;80:31‐43.
  34. De Schauwer C, Meyer E, Cornillie P, De Vliegher S, van de Walle GR, Hoogewijs M, Declercq H, Govaere J, Demeyere K, Cornelissen M, Van Soom A. Optimization of the isolation, culture, and characterization of equine umbilical cord blood mesenchymal stromal cells.. Tissue Eng Part C Methods 2011 Nov;17(11):1061-70.
    pubmed: 21870941doi: 10.1089/ten.tec.2011.0052google scholar: lookup
  35. Renzi S, Riccò S, Dotti S, Sesso L, Grolli S, Cornali M, Carlin S, Patruno M, Cinotti S, Ferrari M. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: a clinical report.. Res Vet Sci 2013 Aug;95(1):272-7.
    pubmed: 23419936doi: 10.1016/j.rvsc.2013.01.017google scholar: lookup
  36. Bonelli F, Meucci V, Divers TJ, Wagner B, Intorre L, Sgorbini M. Kinetics of plasma procalcitonin, soluble CD14, CCL2 and IL-10 after a sublethal infusion of lipopolysaccharide in horses.. Vet Immunol Immunopathol 2017 Feb;184:29-35.
    pubmed: 28166929doi: 10.1016/j.vetimm.2016.12.010google scholar: lookup
  37. Schwartz D, Pusterla N, Jacobsen S, Christopher MM. Analytical validation of a new point-of-care assay for serum amyloid A in horses.. Equine Vet J 2018 Sep;50(5):678-683.
    pubmed: 29344980doi: 10.1111/evj.12807google scholar: lookup
  38. Page AE, Adam E, Arthur R, Barker V, Franklin F, Friedman R, Grande T, Hardy M, Howard B, Partridge E, Rutledge M, Scollay M, Stewart JC, Vale A, Horohov DW. Expression of select mRNA in Thoroughbreds with catastrophic racing injuries.. Equine Vet J 2022 Jan;54(1):63-73.
    pubmed: 33438228doi: 10.1111/evj.13423google scholar: lookup
  39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.. Methods 2001 Dec;25(4):402-8.
    pubmed: 11846609doi: 10.1006/meth.2001.1262google scholar: lookup
  40. Breathnach CC, Sturgill-Wright T, Stiltner JL, Adams AA, Lunn DP, Horohov DW. Foals are interferon gamma-deficient at birth.. Vet Immunol Immunopathol 2006 Aug 15;112(3-4):199-209.
    pubmed: 16621024doi: 10.1016/j.vetimm.2006.02.010google scholar: lookup
  41. Page AE, Stewart JC, Holland RE. The impact of training regimen on the inflammatory response to exercise in 2‐year‐old thoroughbreds.. J Equine Vet 2017;58:78‐83.
  42. Shono S, Gin A, Minowa F, Okubo K, Mochizuki M. The Oxidative Stress Markers of Horses-the Comparison with Other Animals and the Influence of Exercise and Disease.. Animals (Basel) 2020 Apr 3;10(4).
    pmc: PMC7222798pubmed: 32260122doi: 10.3390/ani10040617google scholar: lookup
  43. Sgorbini M, Bonelli F, Marmorini P, Biagi G, Corazza M, Pasquini A. Maternal and neonatal evaluation of derivated reactive oxygen metabolites (d-ROMs) and biological antioxidant potential in the horse.. Theriogenology 2015 Jan 1;83(1):48-51.
    pubmed: 25447151doi: 10.1016/j.theriogenology.2014.07.041google scholar: lookup
  44. Celi P, Sullivan M, Evans D. The stability of the reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests on stored horse blood.. Vet J 2010 Feb;183(2):217-8.
    pubmed: 19010703doi: 10.1016/j.tvjl.2008.09.018google scholar: lookup
  45. Amer J, Goldfarb A, Fibach E. Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells.. Eur J Haematol 2003 Feb;70(2):84-90.
    pubmed: 12581189doi: 10.1034/j.1600-0609.2003.00011.xgoogle scholar: lookup
  46. Serpa PBS, Woolcock A, Taylor SD, Pires Dos Santos A. Validation of a flow cytometric assay to detect intraerythrocytic reactive oxygen species in horses.. Vet Clin Pathol 2021 Mar;50(1):20-27.
    pubmed: 33650208doi: 10.1111/vcp.12976google scholar: lookup
  47. Lilliehöök I, Tvedten HW, Bröjer J, Edner A, Nostell K. Time-related changes in equine neutrophils after experimental endotoxemia: myeloperoxidase staining, size, and numbers.. Vet Clin Pathol 2016 Mar;45(1):66-72.
    pubmed: 26918552doi: 10.1111/vcp.12334google scholar: lookup
  48. Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, Eliopoulos N. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.. Cytotherapy 2014 Feb;16(2):191-202.
    pubmed: 24438900doi: 10.1016/j.jcyt.2013.11.008google scholar: lookup
  49. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    pubmed: 27712399doi: 10.1089/scd.2016.0209google scholar: lookup
  50. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    pubmed: 26964718doi: 10.1016/j.vetimm.2016.02.007google scholar: lookup
  51. Kelmer G, Doherty TJ, Elliott S, Saxton A, Fry MM, Andrews FM. Evaluation of dimethyl sulphoxide effects on initial response to endotoxin in the horse.. Equine Vet J 2008 Jun;40(4):358-63.
    pubmed: 18356128doi: 10.2746/042516408x293501google scholar: lookup
  52. Burrows GE. The effects of repeated administration of Escherichia coli lipopolysaccharides to ponies.. Can J Comp Med 1979 Jul;43(3):321-7.
    pmc: PMC1319896pubmed: 385123
  53. Ward DS, Fessler JF, Bottoms GD, Turek J. Equine endotoxemia: cardiovascular, eicosanoid, hematologic, blood chemical, and plasma enzyme alterations.. Am J Vet Res 1987 Jul;48(7):1150-6.
    pubmed: 3307560
  54. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, Baan CC, Dahlke MH, Hoogduijn MJ. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.. Front Immunol 2012;3:297.
    pmc: PMC3458305pubmed: 23056000doi: 10.3389/fimmu.2012.00297google scholar: lookup
  55. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells.. Front Immunol 2014;5:148.
    pmc: PMC4032901pubmed: 24904568doi: 10.3389/fimmu.2014.00148google scholar: lookup
  56. Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RC, Wu Y. The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke.. Stem Cell Rev Rep 2014 Apr;10(2):295-303.
    pubmed: 24390934doi: 10.1007/s12015-013-9492-xgoogle scholar: lookup
  57. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.. Cells Tissues Organs 2001;169(1):12-20.
    pubmed: 11340257doi: 10.1159/000047856google scholar: lookup
  58. Zheng B, von See MP, Yu E, Gunel B, Lu K, Vazin T, Schaffer DV, Goodwill PW, Conolly SM. Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo.. Theranostics 2016;6(3):291-301.
    pmc: PMC4737718pubmed: 26909106doi: 10.7150/thno.13728google scholar: lookup
  59. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, Wang W, Yerebakan C, Li W, Gaebel R, Li RK, Vollmar B, Steinhoff G, Ma N. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy.. Microvasc Res 2009 May;77(3):370-6.
    pubmed: 19249320doi: 10.1016/j.mvr.2009.02.001google scholar: lookup
  60. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.. Circulation 2003 Aug 19;108(7):863-8.
    pubmed: 12900340doi: 10.1161/01.cir.0000084828.50310.6agoogle scholar: lookup
  61. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs.. Lancet 2004 Mar 6;363(9411):783-4.
    pubmed: 15016490doi: 10.1016/s0140-6736(04)15695-xgoogle scholar: lookup
  62. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, Pittenger MF, van Zijl PC, Huang J, Bulte JW. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia.. Stroke 2008 May;39(5):1569-74.
    pmc: PMC2857730pubmed: 18323495doi: 10.1161/strokeaha.107.502047google scholar: lookup
  63. Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.. Stem Cell Res Ther 2013 Apr 30;4(2):48.
    pmc: PMC3707049pubmed: 23632128doi: 10.1186/scrt198google scholar: lookup
  64. Chen Y, Yu B, Xue G, Zhao J, Li RK, Liu Z, Niu B. Effects of storage solutions on the viability of human umbilical cord mesenchymal stem cells for transplantation.. Cell Transplant 2013;22(6):1075-86.
    pubmed: 23043973doi: 10.3727/096368912x657602google scholar: lookup
  65. Wei Z, Batagov AO, Carter DR, Krichevsky AM. Fetal Bovine Serum RNA Interferes with the Cell Culture derived Extracellular RNA.. Sci Rep 2016 Aug 9;6:31175.
    pmc: PMC4977539pubmed: 27503761doi: 10.1038/srep31175google scholar: lookup

Citations

This article has been cited 1 times.
  1. Mukhopadhyay A, Cook SR, SanMiguel P, Ekenstedt KJ, Taylor SD. TLR4 and MD2 variation among horses with differential TNFα baseline concentrations and response to intravenous lipopolysaccharide infusion.. Sci Rep 2023 Jan 27;13(1):1486.
    doi: 10.1038/s41598-023-27956-ypubmed: 36707633google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.